

Title (en)

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF SYNAPTIC DYSFUNCTION COMPRISING AN OXIME

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON SYNAPTISCHER STÖRUNGEN, DIE OXIMVERBINDUNGEN ENTHALTEN

Title (fr)

COMPOSITION PHARMACEUTIQUE CONTENANT DE L'OXIME, POUR LE TRAITEMENT DE DYSFONCTIONNEMENT SYNAPTIQUE

Publication

EP 1014981 A1 20000705 (EN)

Application

EP 98902893 A 19980205

Priority

- CA 9800094 W 19980205
- US 79725197 A 19970207
- US 79524797 A 19970210
- US 80180197 A 19970214
- US 80180297 A 19970214
- US 80371997 A 19970221
- US 80372197 A 19970221
- US 80372297 A 19970221
- US 80372397 A 19970221
- US 80727397 A 19970228

Abstract (en)

[origin: WO9834615A1] A pharmaceutical composition is provided for treatment of chronic symptoms of synaptic dysfunction and related disease disorders comprising an effective amount of a pharmaceutically acceptable oxime which is physiologically active such as an acetylcholine esterase reactivator optionally in association with an additional pharmacologically active agent. The pharmaceutical composition has wide-ranging applicability in the treatment of withdrawal symptoms due to the cessation of tobacco use, respiratory disease, drug and alcohol addiction, disorders of the central and peripheral nervous systems, treatment of antineoplastic disease as well as the reduction of adverse effects of antineoplastic disease treatment, cardiac disorders and circulatory disease, obesity, fatigue syndromes, endocrine and immune system disorders, dysfunction of gastrointestinal motility and irritable bowel syndrome, and heavy metal poisoning.

IPC 1-7

A61K 31/46

IPC 8 full level

A61K 31/428 (2006.01); **A61K 31/433** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/46** (2006.01); **A61K 31/465** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61P 1/00** (2006.01); **A61P 3/04** (2006.01); **A61P 9/00** (2006.01); **A61P 11/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/32** (2006.01); **A61P 25/34** (2006.01); **A61P 25/36** (2006.01); **A61P 35/00** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07D 417/12** (2006.01)

CPC (source: EP)

A61K 31/44 (2013.01); **A61K 31/46** (2013.01); **A61K 45/06** (2013.01); **A61P 1/00** (2017.12); **A61P 3/04** (2017.12); **A61P 9/00** (2017.12); **A61P 11/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/32** (2017.12); **A61P 25/34** (2017.12); **A61P 25/36** (2017.12); **A61P 35/00** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)

See references of WO 9834615A1

Designated contracting state (EPC)

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 9834615 A1 19980813; AU 5977598 A 19980826; CA 2279531 A1 19980813; EP 1014981 A1 20000705; JP 2001511159 A 20010807

DOCDB simple family (application)

CA 9800094 W 19980205; AU 5977598 A 19980205; CA 2279531 A 19980205; EP 98902893 A 19980205; JP 53346698 A 19980205